Neurologic Disorders Therapeutics Market 2024-2028: Size and Advent of neurostimulation devices; growth driven by the Application, Some of key Companies Positioned Strategically

The neurologic disorders therapeutics market size by Application (CNS and PNS) and Geography (North America, Europe, Asia, and Rest of World (ROW)), is forecast to increase by USD 27.2 billion. The market is expected to grow at a CAGR of   4.49% between 2024 and 2028.

• The neurologic disorders therapeutics market presently relies on traditional antidepressant medications, such as dopamine agonists, acetylcholinesterase inhibitors, tricyclic antidepressants (TCAs), and selective serotonin reuptake inhibitors (SSRIs), to address a diverse range of neurological conditions. Although these drugs offer therapeutic benefits, they carry potential side effects including weight gain, muscle spasms, blurred vision, dry mouth, and drowsiness. Furthermore, these treatments necessitate frequent administration and extended treatment durations, leading to substantial financial burdens for patients. In response to these challenges, research and development efforts have focused on non-invasive neuromodulation devices, which are poised to gain significant clinical significance in the coming years. These innovative technologies, driven by advancements in neuroscience, are of increasing interest to clinicians, healthcare systems, patients, industry, and payers alike.
• The neurologic disorders therapeutics market represents a significant business opportunity due to the rising prevalence of neurological conditions and the unmet medical need for effective treatments. Key market drivers include an aging population, increasing healthcare expenditures, and technological advancements in neurology. Companies focusing on neurologic disorders therapeutics can anticipate robust growth, especially in areas such as neurodegenerative diseases, epilepsy, and pain management. Strategic collaborations, product innovation, and regulatory approvals are essential for market success.

Access the full report to know who are the other key countries segment-wise forecast and historic data

Some of the Key Companies:

• AbbVie Inc.
• Acadia Pharmaceuticals Inc.
• Acorda Therapeutics Inc.
• Bayer AG
• Biogen Inc.
• Eisai Co. Ltd.
• F. Hoffmann La Roche Ltd.
• GlaxoSmithKline Plc
• H Lundbeck AS
• Johnson and Johnson Services Inc.
• Merck KGaA
• Novartis AG
• Otsuka Holdings Co. Ltd.
• Pfizer Inc.
• Sanofi SA
• Takeda Pharmaceutical Co. Ltd.
• Teva Pharmaceutical Industries Ltd.
• UCB SA
• USWM LLC
• Viatris Inc.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/